Ex vivo transfection of mRNA-loaded dendritic cell vaccines against a variety of tumor specific antigens such as telomerase reverse transcriptase (TERT) and the melanoma cell line B16F10 have led to generation of a strong antitumor immune response in murine melanoma models [80,81]. This evidence concerns the gene TERT and melanoma.